Premium
Treatment of latent tuberculosis infection with short‐course regimens in potential living kidney donors
Author(s) -
Simkins Jacques,
DonatoSantana Christian,
Morris Michele Ileana,
Abbo Lilian Margarita,
Camargo Jose Fernando,
Anjan Shweta,
Natori Yoichiro,
Guerra Giselle
Publication year - 2020
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.13244
Subject(s) - medicine , rifapentine , latent tuberculosis , tuberculosis , kidney transplantation , isoniazid , donation , kidney , gastroenterology , mycobacterium tuberculosis , pathology , economics , economic growth
Background Treatment data for latent tuberculosis infection (LTBI) among potential living kidney donors are scarce. Methods This retrospective study was performed to evaluate the prevalence of positive QuantiFERON‐TB Gold In‐Tube (QFT‐GIT) among potential living kidney donors that were screened from 2009 to 2017. We investigated if there was any difference in the time to donation between QFT‐GIT–positive and QFT‐GIT–negative donors. We assessed the regimens used to treat LTBI and whether the recipients of QFT‐GIT–positive donors developed active tuberculosis (TB). Results Forty out of 427 (9%) potential living kidney donors had a positive QFT‐GIT. QFT‐GIT–positive donors were as likely as negative donors to undergo donation (30 [75%] vs 315 [81%], P = .33). The time from QFT‐GIT testing to donation was longer among QFT‐GIT–positive donors (median 221 days [range: 4‐1139] vs 86 days [range: 3‐1887], P = .001). Twelve‐week rifapentine (RPT)/Isoniazid (INH) was the most common treatment used and was not associated with significant adverse reactions. There was a trend toward longer time to donation among QFT‐GIT–positive donors who were treated for LTBI compared with QFT‐GIT–positive donors who were not (252 days [range: 88‐1139] vs 95 days [range: 4‐802], P = .05). Twenty‐nine recipients of QFT‐GIT–positive living kidney donors were evaluated. Eleven of these recipients received kidneys from donors that were not treated for LTBI. Two of these recipients were treated with INH post‐transplantation. Conclusions The time from QFT‐GIT testing to donation was longer among QFT‐GIT–positive donors. The short‐course regimens appear to be excellent options for LTBI treatment among living kidney donors and avoid delaying organ donation further.